Processa Pharmaceuticals Inc (PCSA) Actualités

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabineResults...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that...

Form 8-K - Current report

Processa Pharmaceuticals Provides Product Pipeline and Financial Update

Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety...

Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri

Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde® Studies support potential...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]